Original from: 360dx
LGC on Wednesday said it has acquired DiaMex, a German manufacturer of third-party serology and molecular quality controls for clinical laboratories and blood banks, for an undisclosed amount.
DiaMex provides its Optitrol lines of serology and nucleic acid test third-party controls. According to its website, the firm specializes in panels for blood banks, pediatric diseases, and TORCH (toxoplasmosis, rubella cytomegalovirus, herpes simplex, and HIV) blood screening.
"By acquiring DiaMex, we will now have access to a best-in-class product range [in Optitrol] that complements our own quality control portfolio," Ken Yoon, executive VP and general manager of LGC's diagnostics and genomics unit, said in a statement. He added that the transaction is expected to particularly help the company offer a wider product range in European, Asian-Pacific, and Latin American markets.
In October, UK-based LGC ¡ª which has operations in 14 countries across the US, Europe, and Asia ¡ª struck a deal to develop quality control materials for next-generation sequencing tests with AccuGenomics through its LGC Clinical Diagnostics arm.
